Navigation Links
Corteva Agriscience Signs Agreement with Gaïago to Develop and Distribute Biofungicide Solutions Globally
Date:9/8/2021

Corteva, Inc. (NYSE: CTVA) and Gaïago, a biotechnology company, announced today a multi-year agreement to validate, develop and commercialize biofungicides for farmers worldwide.

Through the agreement, Corteva Agriscience receives an exclusive, global testing license and associated optional commercial rights for a novel biofungicide technology that can help protect grapevines, potatoes, vegetables, and stone and pome fruits against pathogens such as downy mildew, late blight, powdery mildew and botrytis.

“This agreement furthers our commitment to offering farmers biologicals for crop protection, including tested biofungicide solutions that meet Corteva Agriscience’s high standards in Research & Development,” said Rajan Gajaria, Executive Vice President, Business Platforms, Corteva Agriscience. “Our agreement with Gaïago is another step in demonstrating our efforts in building our biological portfolio by collaborating with the leading experts in their fields.”

“Achieving sustainability in agricultural production as well as a resilient food system requires strong collaborations at all levels,” said Jean-Pierre Princen, President of Gaïago. “This agreement with Corteva will speed up the global introduction of one of our natural biocontrol technologies. This novel biofungicide should be key, both to implement integrated pest management strategies and to meet consumers' expectations, whilst helping to preserve high crop yields and increasing farmers’ income. This global collaboration with Corteva, together with the launch of our joint research programs with scientific institutions in Europe, will boost Gaïago’s large-scale Agrosystems regeneration plans, hence restoring soil and plant functions.”

Corteva’s model for developing its best-in-class Biologicals portfolio combines external innovation, R&D collaboration, licensing, and distribution. This agreement demonstrates how Corteva is targeting collaborations that bring a broad range of external technologies, including well-established companies in the Biologicals space to expand access of a complete set of sustainable solutions in line with the Corteva Agriscience 2030 Sustainability Goals.

Terms of the agreement were not disclosed.

About Corteva
Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that provides farmers around the world with the most complete portfolio in the industry - including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability. With some of the most recognized brands in agriculture and an industry-leading product and technology pipeline well positioned to drive growth, the company is committed to working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva Agriscience became an independent public company on June 1, 2019, and was previously the Agriculture Division of DowDuPont. More information can be found at http://www.corteva.com.

Follow Corteva Agriscience on Facebook, Instagram, LinkedIn, Twitter and YouTube.

About Gaïago
Gaïago is a company providing solutions to deliver on its Vision ’Mankind thrives when soils thrive’. Introducing innovative technologies based on the selective activation of microbiology through proprietary formulations, the company strategy is focused on soil revitalization, seed, and plant health. This holistic approach is generating significant agronomic and economic benefits, further amplified with both Carbon sequestration in the soil and Fertilizer uses efficiency. More information at http://www.gaiago.eu.

Follow Gaïago on LinkedIn, Twitter, YouTube, Facebook & Instagram.

Cautionary Statement About Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's growth, product development, and sustainability goals, are forward-looking statements.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (xi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy E. I. du Pont de Nemours and Company liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxii) risks related to COVID-19; (xxiii) risks related to activist stockholders; (xxiv) failure to enforce Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements; and (xxvii) other risks related to the separation from DowDuPont. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K.
09/08/21

TM ® SM Trademarks and service marks of Corteva Agriscience and its affiliated companies, except those of Gaïago.

Read the full story at https://www.prweb.com/releases/corteva_agriscience_signs_agreement_with_gaiago_to_develop_and_distribute_biofungicide_solutions_globally/prweb18173890.htm.


'/>"/>
Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved


Related biology news :

1. Corteva Agriscience and Bejo Sign Agreement on Genome Editing
2. Corteva Agriscience Collaborates with Elemental Enzymes to Provide Farmers with Abiotic Stress Mitigation Technology
3. Encouraging signs for bee biodiversity
4. Light and nanoprobes detect early signs of infection
5. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
6. Leopoldina signs cooperation agreement with the Academy of Science of South Africa
7. BioClaim, Inc. Signs Biometric Software Contract with Amerigroup Florida
8. Switzerland signs the ELIXIR consortium agreement and contributes €35 million
9. Research reveals new understanding, warning signs, and potential treatments for multiple sclerosis
10. A*STAR signs agreement with Nestlé to strengthen food & nutrition R&D in Singapore
11. Quick test finds signs of diarrheal disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: